Tafinlar

Monotherapy or in combination w/ trametinib in patients w/ unresectable or metastatic melanoma w/ BRAF V600 mutation. In combination w/ trametinib for adjuvant treatment of patients w/ melanoma w/ BRAF V600 mutation & involvement of lymph node(s) following complete resection; for advanced NSCLC w/ BRAF V600 mutation; in patients w/ locally advanced or metastatic anaplastic thyroid cancer w/ BRAF V600 mutation & no satisfactory locoregional treatment options; in ped patients ≥1 yr w/ low-grade glioma w/ BRAF V600E mutation who require systemic therapy.

Cap Adult 150 mg bd. Ped patient weighing ≥51 kg 150 bd, 38-50 kg 100 mg bd, 26-37 kg 75 kg bd. Dispersible tab Patient weighing ≥51 kg 150 mg bd, 46-50 kg 130 mg bd, 42-45 kg 110 mg bd, 38-41 kg 100 mg bd, 34-37 kg 90 mg bd, 30-33 kg 80 mg bd, 26-29 kg 70 bd, 22-25 kg 60 mg bd, 18-21 kg 50 mg bd, 14-17 kg 40 mg bd, 10-13 kg 30 mg bd, 8-9 kg 20 mg bd.

Should be taken with food: Take at least 1 hr before or at least 2 hr after meal, leaving an interval of approx 12 hr between doses. Cap: Swallow whole w/ glass of water. Do not chew or crush. Dispersible tab: Take as susp only. Do not swallow whole, chew or crush.

Hypersensitivity.

Targeted Cancer Therapy

L01EC02 - dabrafenib ; Belongs to the class of B-Raf serine-threonine kinase (BRAF) inhibitors. Used in the treatment of cancer.

POM